Ortho Clinical Diagnostics has obtained the CE mark for its Vitros NephroCheck test, a risk assessment tool for predicting development of moderate to severe acute kidney injury (AKI). The NephroCheck is a urine test that provides results in 16 minutes, enabling clinicians to evaluate the risk of AKI quicker than with standard indicators such as serum creatinine and urine output. According to Ortho, this test is the first fully automated test for AKI and is the only test that accurately measures TIMP-2 and IGFB-7, two biomarkers that, when elevated, are highly predictive of kidney stress before damage has occurred. The test can now be run on Ortho’s Vitros 3600/5600 Immunodiagnostic systems in Europe.